Optiver Holding
EWTX icon

Optiver Holding’s Edgewise Therapeutics EWTX Stock Holding History

Optiver Holding’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Buy
369
+108
+41% +$3.72K ﹤0.01% 1632
2026
Q1 		$8.22K Buy
261
+100
+62% +$2.88K ﹤0.01% 1264
2025
Q4 		$4K Sell
161
-307
-66% -$6.16K ﹤0.01% 1533
2025
Q3 		$7.59K Buy
+468
New +$6.64K ﹤0.01% 1462

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Optiver Holding's EWTX Position: Q2 2026 in Review

Optiver Holding increased its Edgewise Therapeutics (EWTX) stake by 41% in Q2 2026, buying an estimated $3.72K and bringing the position to 369 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Optiver Holding first reported a position in EWTX in Q3 2025 and has held it in 4 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Optiver Holding held 369 shares of Edgewise Therapeutics worth $15K as of Q2 2026.
  • Optiver Holding bought 108 Edgewise Therapeutics shares in Q2 2026, an estimated $3.72K.
  • Edgewise Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1632 holding.
  • Optiver Holding first reported a position in Edgewise Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.